Business Description
Huadong Medicine Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE0000011S1
Share Class Description:
SZSE:000963: Class ACompare
Compare
Traded in other countries / regions
000963.China IPO Date
2000-01-27Description
Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine and genetic engineering drugs products. It is also engaged in the wholesale, retail and distribution business of Chinese and western medicine, Chinese herbal medicine, medical apparatus, and instruments. The main business of the company is divided into pharmaceutical business sales and the industry of pharmaceutical. The product portfolio of the company includes Corbrin capsule, Cymusi, New Cyspin, Kasiping, Panlisu, Acarbose, and others.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.88 | |||||
Equity-to-Asset | 0.64 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 0.51 | |||||
Interest Coverage | 35.99 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 5.09 | |||||
Beneish M-Score | -2.46 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.4 | |||||
3-Year EBITDA Growth Rate | 3.5 | |||||
3-Year EPS without NRI Growth Rate | 4 | |||||
3-Year FCF Growth Rate | 6.2 | |||||
3-Year Book Growth Rate | 12.8 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 42.75 | |||||
9-Day RSI | 48.51 | |||||
14-Day RSI | 47.03 | |||||
6-1 Month Momentum % | -6.56 | |||||
12-1 Month Momentum % | -34.35 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.76 | |||||
Quick Ratio | 1.37 | |||||
Cash Ratio | 0.33 | |||||
Days Inventory | 60.67 | |||||
Days Sales Outstanding | 74.51 | |||||
Days Payable | 83.3 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.02 | |||||
Dividend Payout Ratio | 0.17 | |||||
3-Year Dividend Growth Rate | 1.2 | |||||
Forward Dividend Yield % | 2.02 | |||||
5-Year Yield-on-Cost % | 1.6 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 2.17 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 32.19 | |||||
Operating Margin % | 9.39 | |||||
Net Margin % | 7.2 | |||||
FCF Margin % | 4.91 | |||||
ROE % | 14.42 | |||||
ROA % | 8.82 | |||||
ROIC % | 15.9 | |||||
ROC (Joel Greenblatt) % | 43.01 | |||||
ROCE % | 16.53 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 16.88 | |||||
PE Ratio without NRI | 16.71 | |||||
Shiller PE Ratio | 21.52 | |||||
Price-to-Owner-Earnings | 28.14 | |||||
PEG Ratio | 4.64 | |||||
PS Ratio | 1.21 | |||||
PB Ratio | 2.27 | |||||
Price-to-Tangible-Book | 3.16 | |||||
Price-to-Free-Cash-Flow | 24.79 | |||||
Price-to-Operating-Cash-Flow | 13.49 | |||||
EV-to-EBIT | 13.04 | |||||
EV-to-EBITDA | 13.04 | |||||
EV-to-Revenue | 1.18 | |||||
EV-to-FCF | 24.9 | |||||
Price-to-Projected-FCF | 1.61 | |||||
Price-to-DCF (Earnings Based) | 0.77 | |||||
Price-to-DCF (FCF Based) | 0.79 | |||||
Price-to-Median-PS-Value | 0.8 | |||||
Price-to-Graham-Number | 1.53 | |||||
Price-to-Net-Current-Asset-Value | 7.43 | |||||
Earnings Yield (Greenblatt) % | 7.67 | |||||
FCF Yield % | 4.03 | |||||
Forward Rate of Return (Yacktman) % | 1.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Huadong Medicine Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 40,920.06 | ||
EPS (TTM) (Â¥) | 1.682 | ||
Beta | 1.34 | ||
Volatility % | 42.49 | ||
14-Day RSI | 47.03 | ||
14-Day ATR (Â¥) | 0.775138 | ||
20-Day SMA (Â¥) | 27.9235 | ||
12-1 Month Momentum % | -34.35 | ||
52-Week Range (Â¥) | 25.96 - 46.43 | ||
Shares Outstanding (Mil) | 1,754.33 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Huadong Medicine Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Huadong Medicine Co Ltd Stock Events
Event | Date | Price(Â¥) | ||
---|---|---|---|---|
No Event Data |
Huadong Medicine Co Ltd Frequently Asked Questions
What is Huadong Medicine Co Ltd(SZSE:000963)'s stock price today?
The current price of SZSE:000963 is ¥28.40. The 52 week high of SZSE:000963 is ¥46.43 and 52 week low is ¥25.96.
When is next earnings date of Huadong Medicine Co Ltd(SZSE:000963)?
The next earnings date of Huadong Medicine Co Ltd(SZSE:000963) is .
Does Huadong Medicine Co Ltd(SZSE:000963) pay dividends? If so, how much?
The Dividend Yield %  of Huadong Medicine Co Ltd(SZSE:000963) is 2.02% (As of Today), Highest Dividend Payout Ratio of Huadong Medicine Co Ltd(SZSE:000963) was 0.76. The lowest was 0.17. And the median was 0.26. The  Forward Dividend Yield % of Huadong Medicine Co Ltd(SZSE:000963) is 2.02%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |